United Therapeutics’ revenues for the quarter ended June 30, 2005 totaled $30.1 million, representing a 64% increase over the same quarter in 2004.
Net income for the quarter increased 194% over the same quarter in 2004 to $12.2 million, or $0.54 per basic share, with gross sales margins at $26.8 million in the second quarter of 2005, as compared to $16.3 million in the second quarter of 2004.
“Use of Remodulin is increasing as awareness and appreciation of its benefits continue to build at expert centers,” said Dr Roger Jeffs, president and COO. “In addition, we are making good progress with international approvals, post-marketing clinical trials of Remodulin, development of newer formulations of treprostinil and enrollment of the OvaRex pivotal studies.”